How can we improve antibody-based cancer therapy?

Monoclonal antibodies (mAbs) as a class of novel oncology therapeutics are demonstrating clinical efficacy as measured by tumor response (shrinkage in tumor size), and prolongations in progression-free survival (PFS) and overall survival (OS). However, clinical benefits are often limited to when ant...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Yan, Li, Ehrlich, Paula J, Gibson, Raymond, Pickett, Cheryl, Beckman, Robert A
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Landes Bioscience 2009
Konular:
Perspective
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2715179/
https://ncbi.nlm.nih.gov/pubmed/20046576
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller